Navigation Links
Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
Date:6/29/2009

president and chief executive officer of Horizon Therapeutics. "Dr. Sherman will oversee the preparation and submission of the HZT-501 regulatory applications to U.S. and European regulatory authorities, while helping us manage the clinical development of our other pain therapies."

In addition to his Horizon appointment, Dr. Sherman was recently elected President of the Drug Information Association (DIA), a global, nonprofit, multidisciplinary, professional association of approximately 18,000 members which provides a neutral forum for sharing information that optimizes the process of drug development and lifecycle management. He has been a member of the DIA Board of Directors for nearly seven years and in 2001, received the association's "Outstanding Service Award."

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes innovative combination therapies in early- and late-stage development that are designed to improve safety, efficacy and patient compliance. For more information about the company and its products, please visit www.horizontherapeutics.com.


'/>"/>
SOURCE Horizon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use
2. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California
3. Horizon Therapeutics Announces Senior Management Appointments
4. Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
5. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
6. Horizon Therapeutics to Present at UBS Global Life Sciences Conference
7. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
8. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
9. BioHorizons Announces the Purchase of Implant Logic Systems
10. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
11. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
(Date:5/21/2013)... NY (PRWEB) May 21, 2013 Bed bugs ... according to My Cleaning Products, many turn to chemical-based pesticides ... of the health and environmental risks those solutions present, the ... with Bed Bug Bully instead. , According to My ... bugs as they used to be. It shared that the ...
(Date:5/21/2013)... Ontario (PRWEB) May 21, 2013 ... scientists of the ITN to design the study, ... of two key clinical models used in the ... (EEC) and Nasal Allergen Challenge (NAC) models. Although ... by numerous publications, to date no direct comparison ...
(Date:5/21/2013)... SoundConnect is pleased to announce the release ... in Canada. Lync is the next generation of ... and organizations to collaborate and communicate much more easily ... the United States. With the progressive rollout of Lync ... Canada, SoundConnect now offers a complete Microsoft Lync solution ...
Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2SoundConnect Announces Microsoft Lync Release in Canada 2SoundConnect Announces Microsoft Lync Release in Canada 3
... Calif. and BANGALORE, India, July 10, 2011 Life ... that it has launched a regional distribution hub in India ... The new India Distribution Center (IDC), located ... of Life Technologies, products to its thousands of customers in ...
... NATICK, Mass., July 8, 2011 RegenoCELL Therapeutics, Inc. (OTCBB: ... pleased to announce the opening of another state of the ... congestive heart failure and peripheral artery disease with its autologous ... congestive heart failure is administered at the Metropolitan Hospital in ...
... Care Compliance Strategies, Inc. (HCCS) announced today a partnership ... to deliver a series of critical care nursing and ... Management Systems.  This training includes two separate AACN courses: ... Essentials of Nurse Manager Orientation . The courses ...
Cached Biology Technology:Life Technologies Launches New Distribution Center in India 2Life Technologies Launches New Distribution Center in India 3RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece 2RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece 3HCCS Partners with American Association of Critical Care Nurses (AACN) to Offer Nurse Training 2HCCS Partners with American Association of Critical Care Nurses (AACN) to Offer Nurse Training 3
(Date:5/20/2013)... MINNEAPOLIS/ST. PAUL (MAY 20, 2013) University of Minnesota ... of Minnesota, in partnership with the University,s Brain Tumor ... peripheral nerve sheath tumors (MPNST) that allow them to ... of cancer. , The research was published this week ... the Sleeping Beauty transposon method, researchers in the lab ...
(Date:5/20/2013)... New research suggests that a compound abundant in the ... death. , By altering a very specific step ... into normal cells that die as scheduled. , One ... process that would cause them to die on a ... study in cells, led by Ohio State University researchers, ...
(Date:5/20/2013)... study conducted at the University of Bristol and published ... sheds light on how the brain and inner ... Bristol,s School of Earth Sciences, together with Tom Hbner ... brains of 150 million year old dinosaurs. , The ... Dysalotosaurus lettowvorbecki : a very young (juvenile) individual ...
Breaking Biology News(10 mins):U of M researchers develop model for better testing, targeting of MPNST 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3Fossil brain teaser 2
... University of Santiago de Compostela (USC) have studied the ... show that the principal goal of young people is ... antisocial among them place greater importance on popularity with ... on are to do with leaving home, work and ...
... ulcers, one of the ,neglected tropical diseases, left aside by ... in poor regions. But then more attention has to be ... rules of the World Health Organization urgently need to be ... Medicine (ITM), based on ten years of research in Congo. ...
... This release is available in Spanish . ... receive--in addition to what foods you eat--all can influence the ... for optimum health. In a preliminary and apparently first-of-its-kind study, ... colleagues have developed a preliminary model that predicts an individual,s ...
Cached Biology News:Teenagers want to finish their studies and leave home 2WHO guidelines on Buruli ulcer need adjustment 2Model predicts individual's vitamin D needs 2
... 10X BlueJuice Gel Loading ... easy loading and tracking ... agarose or native polyacrylamide ... features higher density sucrose ...
... 3F10B10. Immunogen: Synthetic peptide ... of JAB1 (Jun activation domain-binding ... Specific for the JAB1 protein. ... 293T Jurkat cell lysates). ...
... TOPO Cloning is ... available for cloning PCR ... and Zero Blunt TOPO ... and activated with topoisomerase ...
... Conjugated peptides or recombinant proteins are ... produce antibodies in 2 rabbits. pre-immune and ... test until the titer reaches 1:4,000 Western ... Protein G purification Antibodies are eluted using ...
Biology Products: